Full-Time

Director of Agentic AI

Posted on 8/16/2025

Varian

Varian

5,001-10,000 employees

Tech-enabled radiation oncology hardware and software

Compensation Overview

$180k - $270k/yr

+ Commission

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

In Person

Category
AI & Machine Learning (2)
,
Required Skills
LLM
Python
Tensorflow
Pytorch
Julia
C/C++
Reinforcement Learning
Requirements
  • PhD degree in Computer Science, Artificial Intelligence, Robotics, Machine Learning, Computational Neuroscience, or a related field.
  • Deep understanding of agentic AI, including multi-agent systems, reinforcement learning, and autonomous decision-making.
  • Strong grasp of AI planning, reasoning, and self-improving systems.
  • Experience with Large Language Models (LLMs), cognitive architectures, and human-AI interaction.
  • Proficiency in machine learning frameworks (e.g., PyTorch, TensorFlow).
  • Strong coding ability in Python, C++, or Julia for AI development.
  • Experience with simulation environments (e.g., OpenAI Gym, MuJoCo) and real-world agent deployment.
  • Familiarity with knowledge graphs, neurosymbolic AI, and autonomous decision models.
  • Ability to define and drive the long-term vision for agentic AI development.
  • Proven experience in leading AI research teams and cross-functional innovation projects.
  • Strong stakeholder management, including communication with C-suite executives, researchers, engineers, and regulatory bodies.
  • Track record of translating AI advancements into commercial products and enterprise solutions.
  • Experience with AI-driven business transformation and innovation strategy.
  • Knowledge of industry-specific AI applications in healthcare, finance, robotics, cybersecurity, and autonomous systems.
  • Ability to evaluate AI investments, partnerships, and M&A opportunities.
  • 5+ years of experience in AI research, development, or enterprise AI strategy.
  • Proven track record of developing and deploying AI-driven autonomous systems.
  • Experience in patent filing, research publications, or AI product development.
Responsibilities
  • Define and drive the strategic roadmap for Agentic AI applications in healthcare, ensuring alignment with clinical, operational, and regulatory priorities.
  • Develop and oversee AI-driven autonomous and semi-autonomous systems that enhance decision-making, workflow automation, and personalized patient care.
  • Collaborate with C-level executives, product leaders, and clinicians to identify high-impact use cases and ensure AI solutions deliver measurable value.
  • Lead the design, development, and deployment of next-generation Agentic AI models that can reason, plan, and act autonomously within healthcare settings.
  • Work closely with data scientists, software engineers, clinicians, and regulatory teams to bridge AI innovation with real-world medical applications.
  • Oversee the integration of large-scale multimodal AI systems, leveraging medical imaging, electronic health records (EHR), real-time monitoring, and other healthcare data sources.
  • Partner with academic institutions, industry leaders, and healthcare providers to advance Agentic AI capabilities and adoption.
  • Guide the transition from AI research to scalable, real-world deployments in hospitals, diagnostics, and digital health platforms.
  • Define key performance metrics (KPIs) and clinical validation benchmarks for AI-driven autonomous systems.
  • Represent the company in AI and healthcare conferences, thought leadership initiatives, and policy discussions.
  • Build and lead a world-class team of AI researchers, engineers, and domain experts focused on Agentic AI innovations.
  • Foster a culture of innovation, continuous learning, and interdisciplinary collaboration.
  • Mentor and develop emerging AI talent, driving excellence in both research and product development.
  • Foster research in AI safety, reliability, and interpretability to ensure models adhere to clinical-grade performance and ethical standards.
  • Ensure compliance with global healthcare AI regulations, including FDA, MDR, HIPAA, and emerging AI safety frameworks.
Desired Qualifications
  • Entrepreneurial Mindset: The ability to identify and capitalize on emerging AI business opportunities, often requiring out-of-the-box thinking and an innovative approach.
  • Global Perspective: Knowledge of global AI markets, regulations, and business practices, as well as experience in expanding AI businesses across international markets.

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Simplify Jobs

Simplify's Take

What believers are saying

  • Telix collaboration integrates PET imaging with Ethos adaptive radiotherapy.
  • Halcyon installations expand into Saudi Arabia and Sri Lanka markets.
  • TrueBeam FDA clearance treats osteoarthritis for 33 million US patients.

What critics are saying

  • EU MDR Class III reclassification halts OaaS rollouts, cuts 25% renewals.
  • Eleksia cyclotrons capture 40% of Varian's $2B proton backlog by Q4 2026.
  • ViewRay APAC linacs undercut Halcyon with 30% faster treatments by mid-2026.

What makes Varian unique

  • Varian's ProBeam system powers New York Proton Center with $115M deal.
  • HyperSight imaging enhances Ethos, Halcyon, Edge, TrueBeam precision.
  • IntelliBlate microwave ablation creates controlled spherical zones for oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Company News

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.

PR Newswire
Jul 29th, 2024
Varian Announces Future-Focused, Integrated Microwave Ablation Ecosystem With Intelliblate

PALO ALTO, Calif., July 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announces receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, intended for ablation of soft tissue. Designed to provide clinicians with greater predictability, precision, and control during their procedures, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation.IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. With the option to utilize a single or dual probes – each with linked or independent controls – IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. Precision and control are amplified by the Ximitry probe, which enables innovative features such as Laser Disk Alignment and intuitive LED indicators.The compact, versatile design and intuitive interface of IntelliBlate delivers a portable and flexible system that reduces barriers for this important treatment method. Modular elements provide the flexibility for clinicians to expand their treatment capabilities to meet changing clinical demands, all while keeping control over operational efficiency throughout the ablation procedure."IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation," says Dr

PR Newswire
May 2nd, 2024
Together With Siemens Healthineers, Varian Showcases Commitment To Embracing Innovation And Enhancing Outcomes At Estro 2024

PALO ALTO, Calif., May 2, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, will showcase its ongoing commitment to embracing innovation and enhancing outcomes for cancer care teams and their patients at this year's 2024 European Society for Radiation Oncology (ESTRO) annual meeting, which will take place from May 3 to 7 in Glasgow, Scotland.With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1. Radiotherapy is an integral part of therapeutic treatments for approximately 50% of the patients diagnosed with cancer, yet many countries have inadequate availability of radiotherapy treatment2. Varian is working in collaboration with healthcare providers to change that statistic by creating innovative and integrated solutions to help bring treatment options to those communities who need it most."As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian. "By combining the expertise of the leading imaging and radiotherapy companies, we have the ability to achieve much more than any individual cancer care company by driving connection throughout the entire care continuum."At the ESTRO meeting, Varian will present a range of solutions that will enhance the care continuum, including:HyperSight imaging solution is now available as an optional feature on Ethos, Halcyon, Edge, and TrueBeam radiotherapy platforms. Delivering a revolution in resolution, HyperSight imaging offers superior image quality, enhanced contrast, and faster image acquisition compared to conventional Varian linear-accelerator-based imaging systems.is now available as an optional feature on Ethos, Halcyon, Edge, and TrueBeam radiotherapy platforms. Delivering a revolution in resolution, HyperSight imaging offers superior image quality, enhanced contrast, and faster image acquisition compared to conventional Varian linear-accelerator-based imaging systems

INACTIVE